Cristina Csimma, PharmD, MHP, is a biopharmaceutical leader and strategic advisor with decades of experience in biotechnology, large pharma and venture capital.
Dr. Csimma serves as a Board Director of Neuralstem Inc. (NASDAQ: CUR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), and T1D Exchange. She also serves on the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee, the Executive Oversight Board of the National Institutes of Health’s NeuroNEXT, the External Advisory Board of the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard, and the TREAT-NMD Advisory Committee for Therapeutics, where she was the founding chair.
Previously, Dr. Csimma was Executive Chair of the Board of Directors of Exonics Therapeutics (acquired by Vertex), Inc., as well as a board member of Juniper Pharmaceuticals, Inc. (acquired by Catalent), Vtesse Inc. (acquired by Sucamp now Mallinkrodt), and Cydan, where she was also the founding Chief Executive Officer and President. Earlier in her career, Dr. Csimma held roles with Clarus Ventures LLC (now Blackstone), Virdante Pharmaceuticals, Inc., Wyeth (now Pfizer), Genetics Institute, and Dana-Farber Cancer Institute.
Dr. Csimma holds a Doctor of Pharmacy and a Bachelor of Science from Massachusetts College of Pharmacy, as well as a Master of Health Professions from Northeastern University.